Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.36 |
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28380576 | 1.00 | TUBB1 (0.47) | TUBB1FKBP1AELANEXIAPMEN1 | |
| SCHEMBL22283983 | 1.00 | TUBB1 (0.47) | TUBB1FKBP1AELANEXIAPMEN1 | |
| SCHEMBL28380575 | 1.00 | TUBB1 (0.47) | TUBB1FKBP1AELANEXIAPMEN1 | |
| SCHEMBL22283984 | 1.00 | TUBB1 (0.47) | TUBB1FKBP1AELANEXIAPMEN1 | |
| SCHEMBL28381670 | 1.00 | TUBB1 (0.47) | TUBB1FKBP1AELANEXIAPMEN1 | |
| SCHEMBL13681991 | 0.95 | TUBB1 (0.46) | TUBB1FKBP1AELANEMEN1KMT2A | |
| SCHEMBL88749 | 0.95 | TUBB1 (0.46) | TUBB1FKBP1AELANEMEN1KMT2A | |
| SCHEMBL58625 | 0.95 | TUBB1 (0.46) | TUBB1FKBP1AELANEMEN1KMT2A | |
| SCHEMBL17734005 | 0.95 | TUBB1 (0.46) | TUBB1FKBP1AELANEMEN1KMT2A | |
| SCHEMBL57624 | 0.91 | KMT2A (0.43) | TUBB1FKBP1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-22 | — | — | US | disclosed |
| EP-3666787-B1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3925668-A1 | HEMIASTERLIN DERIVATIVE HAVING CYSTEINE RESIDUE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-3666787-A1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SHBG, CYP11A1, CYP11B1 | TUBB1 1472/4885FKBP1A 221/4885ELANE 2944/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885FKBP1A 1128/4885ELANE 3697/4885 |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885FKBP1A 1128/4885ELANE 3697/4885 |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885FKBP1A 1128/4885ELANE 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.